Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
GSK PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GSK PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
GSK PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,684 | 315 | - | |
Low | Rs | 1,231 | 228 | - | |
Sales per share (Unadj.) | Rs | 191.9 | 93.8 | - | |
Earnings per share (Unadj.) | Rs | 35.9 | -23.6 | - | |
Cash flow per share (Unadj.) | Rs | 39.8 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 32.00 | 0 | - | |
Avg Dividend yield | % | 2.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 102.9 | 73.6 | - | |
Shares outstanding (eoy) | m | 169.41 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 2.9 | 262.4% | |
Avg P/E ratio | x | 40.6 | -11.5 | -353.8% | |
P/CF ratio (eoy) | x | 36.7 | -13.9 | -264.6% | |
Price / Book Value ratio | x | 14.2 | 3.7 | 384.2% | |
Dividend payout | % | 89.2 | 0 | - | |
Avg Mkt Cap | Rs m | 246,858 | 45,814 | 538.8% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 5,950 | 2,875 | 206.9% | |
Avg. sales/employee | Rs Th | 0 | 3,688.3 | - | |
Avg. wages/employee | Rs Th | 0 | 669.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -929.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 32,517 | 15,834 | 205.4% | |
Other income | Rs m | 1,007 | 111 | 907.8% | |
Total revenues | Rs m | 33,524 | 15,945 | 210.2% | |
Gross profit | Rs m | 8,033 | -2,744 | -292.8% | |
Depreciation | Rs m | 658 | 683 | 96.2% | |
Interest | Rs m | 18 | 429 | 4.2% | |
Profit before tax | Rs m | 8,364 | -3,745 | -223.3% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,288 | 234 | 977.5% | |
Profit after tax | Rs m | 6,076 | -3,990 | -152.3% | |
Gross profit margin | % | 24.7 | -17.3 | -142.6% | |
Effective tax rate | % | 27.4 | -6.2 | -437.7% | |
Net profit margin | % | 18.7 | -25.2 | -74.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,943 | 11,597 | 215.1% | |
Current liabilities | Rs m | 13,264 | 6,525 | 203.3% | |
Net working cap to sales | % | 35.9 | 32.0 | 112.1% | |
Current ratio | x | 1.9 | 1.8 | 105.8% | |
Inventory Days | Days | 97 | 111 | 87.7% | |
Debtors Days | Days | 216 | 124 | 174.2% | |
Net fixed assets | Rs m | 6,988 | 6,760 | 103.4% | |
Share capital | Rs m | 1,694 | 74 | 2,304.4% | |
Net worth | Rs m | 17,430 | 12,428 | 140.2% | |
Long term debt | Rs m | 0 | 4,367 | 0.0% | |
Total assets | Rs m | 31,930 | 23,477 | 136.0% | |
Interest coverage | x | 462.6 | -7.7 | -5,982.6% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.0 | 0.7 | 151.0% | |
Return on assets | % | 19.1 | -15.2 | -125.8% | |
Return on equity | % | 34.9 | -32.1 | -108.6% | |
Return on capital | % | 48.1 | -19.8 | -242.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,842 | 1,352 | 358.3% | |
From Investments | Rs m | 8,079 | -415 | -1,946.7% | |
From Financial Activity | Rs m | -15,433 | 3,964 | -389.4% | |
Net Cashflow | Rs m | -2,512 | 4,900 | -51.3% |
Compare GSK PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare GSK PHARMA With: BROOKS LAB AARTI DRUGS S.S.ORGANICS AURO LAB. EMMESSAR CHM
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.